BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 38580329)

  • 1. Combining CRISPR-Cas9 and TCR exchange to generate a safe and efficient cord blood-derived T cell product for pediatric relapsed AML.
    Lo Presti V; Meringa A; Dunnebach E; van Velzen A; Moreira AV; Stam RW; Kotecha RS; Krippner-Heidenreich A; Heidenreich OT; Plantinga M; Cornel A; Sebestyen Z; Kuball J; van Til NP; Nierkens S
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38580329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRISPR-based gene disruption and integration of high-avidity, WT1-specific T cell receptors improve antitumor T cell function.
    Ruggiero E; Carnevale E; Prodeus A; Magnani ZI; Camisa B; Merelli I; Politano C; Stasi L; Potenza A; Cianciotti BC; Manfredi F; Di Bono M; Vago L; Tassara M; Mastaglio S; Ponzoni M; Sanvito F; Liu D; Balwani I; Galli R; Genua M; Ostuni R; Doglio M; O'Connell D; Dutta I; Yazinski SA; McKee M; Arredouani MS; Schultes B; Ciceri F; Bonini C
    Sci Transl Med; 2022 Feb; 14(631):eabg8027. PubMed ID: 35138911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Grade Production of Wilms' Tumor-1 Loaded Cord Blood-Derived Dendritic Cells to Prevent Relapse in Pediatric AML After Cord Blood Transplantation.
    Plantinga M; Lo Presti V; de Haar CG; Dünnebach E; Madrigal A; Lindemans CA; Boelens JJ; Nierkens S
    Front Immunol; 2020; 11():559152. PubMed ID: 33101274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemia.
    Calviño C; Ceballos C; Alfonso A; Jauregui P; Calleja-Cervantes ME; San Martin-Uriz P; Rodriguez-Marquez P; Martin-Mallo A; Iglesias E; Abizanda G; Rodriguez-Diaz S; Martinez-Turrillas R; Illarramendi J; Viguria MC; Redondo M; Rifon J; Villar S; Lasarte JJ; Inoges S; Lopez-Diaz de Cerio A; Hernaez M; Prosper F; Rodriguez-Madoz JR
    Front Immunol; 2023; 14():1270843. PubMed ID: 37795087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. WT1-specific TCRs directed against newly identified peptides install antitumor reactivity against acute myeloid leukemia and ovarian carcinoma.
    van Amerongen RA; Hagedoorn RS; Remst DFG; Assendelft DC; van der Steen DM; Wouters AK; van de Meent M; Kester MGD; de Ru AH; Griffioen M; van Veelen PA; Falkenburg JHF; Heemskerk MHM
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35728869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune responses to WT1 in patients with AML or MDS after chemotherapy and allogeneic stem cell transplantation.
    Casalegno-Garduño R; Schmitt A; Spitschak A; Greiner J; Wang L; Hilgendorf I; Hirt C; Ho AD; Freund M; Schmitt M
    Int J Cancer; 2016 Apr; 138(7):1792-801. PubMed ID: 26519872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells.
    Legut M; Dolton G; Mian AA; Ottmann OG; Sewell AK
    Blood; 2018 Jan; 131(3):311-322. PubMed ID: 29122757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody.
    Augsberger C; Hänel G; Xu W; Pulko V; Hanisch LJ; Augustin A; Challier J; Hunt K; Vick B; Rovatti PE; Krupka C; Rothe M; Schönle A; Sam J; Lezan E; Ducret A; Ortiz-Franyuti D; Walz AC; Benz J; Bujotzek A; Lichtenegger FS; Gassner C; Carpy A; Lyamichev V; Patel J; Konstandin N; Tunger A; Schmitz M; von Bergwelt-Baildon M; Spiekermann K; Vago L; Jeremias I; Marrer-Berger E; Umaña P; Klein C; Subklewe M
    Blood; 2021 Dec; 138(25):2655-2669. PubMed ID: 34280257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generation of donor-derived Wilms tumor antigen 1-specific cytotoxic T lymphocytes with potent anti-leukemia activity for somatic cell therapy in children given haploidentical stem cell transplantation: a feasibility pre-clinical study.
    Ferulli F; Tanzi M; Turin I; Montini E; Rosti V; Acquafredda G; Lisini D; Compagno F; Boghen S; Licari A; Marseglia G; Zecca M; Montagna D
    Cytotherapy; 2019 Sep; 21(9):958-972. PubMed ID: 31279696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant.
    Chapuis AG; Egan DN; Bar M; Schmitt TM; McAfee MS; Paulson KG; Voillet V; Gottardo R; Ragnarsson GB; Bleakley M; Yeung CC; Muhlhauser P; Nguyen HN; Kropp LA; Castelli L; Wagener F; Hunter D; Lindberg M; Cohen K; Seese A; McElrath MJ; Duerkopp N; Gooley TA; Greenberg PD
    Nat Med; 2019 Jul; 25(7):1064-1072. PubMed ID: 31235963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biased usage of BV gene families of T-cell receptors of WT1 (Wilms' tumor gene)-specific CD8+ T cells in patients with myeloid malignancies.
    Tanaka-Harada Y; Kawakami M; Oka Y; Tsuboi A; Katagiri T; Elisseeva OA; Nishida S; Shirakata T; Hosen N; Fujiki F; Murao A; Nakajima H; Oji Y; Kanda Y; Kawase I; Sugiyama H
    Cancer Sci; 2010 Mar; 101(3):594-600. PubMed ID: 20132220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation of a cord blood-derived Wilms Tumor 1 dendritic cell vaccine for AML patients treated with allogeneic cord blood transplantation.
    de Haar C; Plantinga M; Blokland NJ; van Til NP; Flinsenberg TW; Van Tendeloo VF; Smits EL; Boon L; Spel L; Boes M; Boelens JJ; Nierkens S
    Oncoimmunology; 2015 Nov; 4(11):e1023973. PubMed ID: 26451309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous Deletion of Endogenous TCRαβ for TCR Gene Therapy Creates an Improved and Safe Cellular Therapeutic.
    Morton LT; Reijmers RM; Wouters AK; Kweekel C; Remst DFG; Pothast CR; Falkenburg JHF; Heemskerk MHM
    Mol Ther; 2020 Jan; 28(1):64-74. PubMed ID: 31636040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene Editing of Checkpoint Molecules in Cord Blood-Derived Dendritic Cells and CD8
    Lo Presti V; Cutilli A; Dogariu Y; Müskens KF; Dünnebach E; van den Beemt DAMH; Cornel AM; Plantinga M; Nierkens S
    CRISPR J; 2022 Jun; 5(3):435-444. PubMed ID: 35686979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Wilms' tumor gene 1 is an independent prognostic factor for pediatric acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation.
    Deng DX; Wen JJ; Cheng YF; Zhang XH; Xu LP; Wang Y; Yan CH; Chen YH; Chen H; Han W; Wang FR; Wang JZ; Qin YZ; Liu KY; Huang XJ; Zhao XS; Mo XD
    BMC Cancer; 2021 Mar; 21(1):292. PubMed ID: 33740924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR.
    Stenger D; Stief TA; Kaeuferle T; Willier S; Rataj F; Schober K; Vick B; Lotfi R; Wagner B; Grünewald TGP; Kobold S; Busch DH; Jeremias I; Blaeschke F; Feuchtinger T
    Blood; 2020 Sep; 136(12):1407-1418. PubMed ID: 32483603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRISPR/Cas9-medaited knockout of endogenous T-cell receptor in Jurkat cells and generation of NY-ESO-1-specific T cells: An in vitro study.
    Safarzadeh Kozani P; Shokrgozar MA; Evazalipour M; Roudkenar MH
    Int Immunopharmacol; 2022 Sep; 110():109055. PubMed ID: 35853277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One-step CRISPR-Cas9-mediated knockout of native TCRαβ genes in human T cells using RNA electroporation.
    Flumens D; Campillo-Davo D; Janssens I; Roex G; De Waele J; Anguille S; Lion E
    STAR Protoc; 2023 Mar; 4(1):102112. PubMed ID: 36853667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD4(+)and CD8(+)T-cell reactions against leukemia-associated- or minor-histocompatibility-antigens in AML-patients after allogeneic SCT.
    Steger B; Milosevic S; Doessinger G; Reuther S; Liepert A; Braeu M; Schick J; Vogt V; Schuster F; Kroell T; Busch DH; Borkhardt A; Kolb HJ; Tischer J; Buhmann R; Schmetzer H
    Immunobiology; 2014 Apr; 219(4):247-60. PubMed ID: 24315637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-introduced functional CCR2 potentiates in vivo anti-lung cancer functionality mediated by T cells double gene-modified to express WT1-specific T-cell receptor.
    Asai H; Fujiwara H; An J; Ochi T; Miyazaki Y; Nagai K; Okamoto S; Mineno J; Kuzushima K; Shiku H; Inoue H; Yasukawa M
    PLoS One; 2013; 8(2):e56820. PubMed ID: 23441216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.